Portuguese
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
anthraquinone/náusea
O link é salvo na área de transferência
10 resultados
Effect of anthraquinone derivatives on canine and rat intestinal motility.
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
The effects on gastrointestinal motility of 3 senna preparations containing 18% oxidized Ca-sennosides, 60% Ca-sennosides, or pure sennosides A + B were tested in dogs and rats as measured by electromyography. Oral administration of the oxidized products in the fasted animal increased the activity
Phase I study of mitoxantrone on a daily X 5 schedule.
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
Mitoxantrone (NSC-301739) is a synthetic amino anthraquinone DNA intercalater active in several experimental tumor systems. Thirty-three patients with advanced cancer received the drug on a daily X 5 schedule. Myelosuppression, especially leukopenia, was the dose-limiting toxicity and was
[Percutaneous endoscopic colopexy--a new treatment possibility for volvulus of the sigmoid].
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
An 83-year-old woman, largely bedridden since a stroke 2 years before, was hospitalized because of upper abdominal pain, nausea and obstipation. She had regularly been taking laxatives of the anthraquinone type. She had a fever of 38.6 degrees C and leukocytosis (14,900/microliters). Radiological
A randomized trial comparing mitoxantrone with doxorubicin in patients with stage IV breast cancer.
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
Mitoxantrone (Novantrone; dihydroxyanthracenedione) is an anthraquinone previously shown to be active in human breast cancer. It appears to have less toxicity than doxorubicin. Results of this phase II-III randomized cross-over trial to determine the relative efficacy and toxicity of mitoxantrone in
Mitoxantrone: a phase II study in the treatment of patients with advanced breast carcinoma and other solid tumours.
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
A phase II study of mitoxantrone, an anthraquinone derivative with structural similarities to adriamycin, has been carried out in 34 patients with advanced breast carcinoma and other malignancies. The first 20 patients were treated with a starting dose of 12 mg/m2 by IV infusion repeated every 3
[Phase II study of mitoxantrone].
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
A phase II clinical trial of an anthraquinone, mitoxantrone was performed in a total of 31 patients with various advanced solid tumors and 2 patients with malignant lymphomas refractory to extensive prior chemotherapies. Mitoxantrone was administered at dosages of 2 to 4 mg/m2 with a 5-day schedule
Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study.
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
Mitoxantrone (Novantrone; dihydroxyanthracenedione) is a substituted anthraquinone with a spectrum of activity similar to doxorubicin in experimental tumors. One hundred and seventy three patients with advanced breast cancer and no prior cytotoxic therapy for advanced disease entered a phase II
[Mitoxantrone in a combination regimen in advanced breast cancer].
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
The new anthracendione mitoxantrone, an anthraquinone derivate with structural similarities to doxorubicin (adriamycin) is active in the treatment of patients with metastatic breast cancer. It has less acute toxicity than doxorubicin, may be non cross resistant with doxorubicin and appears to have
Randomized controlled trial of Cassia alata Linn. for constipation.
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
Cassia alata Linn. is a medical plant. Its leaves have been claimed to be effective as a laxative. The studies done so far have shown no toxicity as a result of consuming Cassia alata Linn. leaves. The plant has been found to contain anthraquinones, presumed to be the active ingredient causing the
Mitoxantrone for the treatment of advanced breast cancer: single-agent therapy in previously untreated patients.
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
Mitoxantrone (dihydroxyanthracenedione) is a substituted anthraquinone with a similar spectrum of activity to adriamycin in experimental tumours. One hundred and thirty-four patients with advanced breast cancer and no prior chemotherapy for advanced disease were treated with mitoxantrone (14 mg/m2
O mais completo banco de dados de ervas medicinais apoiado pela ciência
- Funciona em 55 idiomas
- Curas herbais apoiadas pela ciência
- Reconhecimento de ervas por imagem
- Mapa GPS interativo - marcar ervas no local (em breve)
- Leia publicações científicas relacionadas à sua pesquisa
- Pesquise ervas medicinais por seus efeitos
- Organize seus interesses e mantenha-se atualizado com as notícias de pesquisa, testes clínicos e patentes
Digite um sintoma ou doença e leia sobre ervas que podem ajudar, digite uma erva e veja as doenças e sintomas contra os quais ela é usada.
* Todas as informações são baseadas em pesquisas científicas publicadas
